dealing with economic and financial crises that have an adverse impact on population mental health.

1 Wilkinson R. Why is violence more common where inequality is greater? Ann NY Acad Sci 2004; 1036: 1–12.


Homicide rates and income inequality

There is evidence that psychosocial factors other than those discussed by Swinson et al 3 affect homicide rates and it is important to know whether these disproportionately affect individuals diagnosed as mentally ill. Specifically, there is evidence that income inequality strongly influences rates of violent crime, including homicide.2 Wilkinson & Pickett have claimed that changes in inequality also influence rates of substance misuse.3 It is thus important to know whether the increase in homicide rates described by Swinson et al could be caused by those with psychiatric problems being ‘left further behind’ in terms of income and/or social status.


2 Wilkinson R. Why is violence more common where inequality is greater? Ann NY Acad Sci 2004; 1036: 1–12.


Authors’ reply: We were looking for factors which corresponded to the overall rise in homicides in people with psychoses; factors which showed increases of a similar magnitude, over a similar timescale. This was the case for drug misuse, allowing us to infer an association. Evidence has been found linking income inequality to both violent crime1 and rates of substance misuse,2 although this has been disputed and there is controversy3 over the validity of the association found between income inequality and mental illness.4 There has been a marked increase in income inequality in recent years5 but, from the data which we have available to us, we are unable to comment as to whether this is also the case among those with mental illness, and whether there is any causal association with homicide rates. In future research we hope to explore the data using deprivation indices which might provide further information on any association between income inequality, mental illness and homicide.


Observational BALANCE

We read with interest Kessing et al’s timely and welcome paper1 supporting, by way of observational cohort study, the findings of BALANCE.2 Lithium again is shown to be superior to valproate for the management of bipolar disorder. The strength in this case comes from bridging the gap between the relatively brief follow-up in randomised control trials (RCTs) and the real-life situation faced by clinicians managing a lifelong illness of unpredictable course. Although the enriched study design in BALANCE aimed to maximise the generalisability of the findings to a clinical population, limitations inevitably remained in terms of including patients who had shown a differential previous response to either lithium or valproate, diagnostic heterogeneity within the sample population, and frequency of comorbidity compared with the general population. The limitations of observational cohort studies are multiple and well documented. One key concern is confounding by indication, but more general problems exist with group biases and masking of cause and effect relationships.

Kessing et al used ‘switch to’ and ‘add on’ as proxy outcomes for the efficacy of mood stabilisers. It would have been interesting, if possible, to separate the ‘switch to’ group from the ‘add on’ groups. The ‘add on’ outcome probably represents a treatment failure; however ‘switch to’ is likely to be a combination of lack of efficacy and poor tolerability. Indeed, their findings suggest that the initial, very rapid increase in incidence of switch/add on is related to tolerability rather than efficacy, whereas in BALANCE this finding would have been lost by drop-out during the run-in period. This is unlikely, however, to explain the superiority of lithium that is clearly present in both outcome measures.

It was previously argued that observational studies would overestimate treatment effects and that they hold little value in assessing therapies; however, comparative studies with RCTs, across various branches of medicine have now dismissed this.3 This sort of complementary approach, reconfirming findings from RCTs over long follow-up periods, is an important addition to the evidence base for treatment. This is especially true in areas where the disorder under investigation is chronic relapsing–remitting, and when the exclusion criteria of RCTs can often mean that external validity is low. If, as has been suggested, bipolar disorder is a heterogeneous condition with subtypes associated with preferential response to specific mood stabilisers4 (which can be identified by symptoms, clinical course and family history), then the observational study carries even more weight when compared with the RCT as it ‘allocates’ patients to treatments on the basis of